A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
Healthy, Renal Insufficiency
About this trial
This is an interventional basic science trial for Healthy
Eligibility Criteria
Inclusion Criteria: Normal Participants: Healthy male and female participants as determined by physical examination Participants with normal renal function assessed by estimated glomerular filtration rate (eGFR) ≥ 90 milliliter per minute (mL/min). Body mass index (BMI) ≥ 19.0 and ≤ 40.0 kilograms per meter squared (kg/m²) Male participants who agree to use contraception and female participants of child bearing potential must agree to use contraceptive methods and women not of child bearing potential can participate. Participants with Renal Impairment: Have acceptable blood pressure (BP) and pulse rate, as determined by the investigator Participants with type 2 diabetes must have a glycated hemoglobin (HbA1c) ≥ 5.0% and ≤ 11.5% Are males or females with severe renal impairment as determined by a stable eGFR <30 mL/min, not requiring hemodialysis OR Are males or females with end-stage renal disease (have received hemodialysis for at least 3 months) Exclusion Criteria: Have known allergies to LY3437943 or related compounds Have a current, functioning organ transplant. Nonfunctional renal allografts may be allowed Have any abnormality in the 12-lead electrocardiogram (ECG) Are women with a positive pregnancy test or women who are lactating
Sites / Locations
- Orange County Research Center
- Clinical Pharmacology of Miami
- Orlando Clinical Research Center
- Nucleus Networks
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
LY3437943 (Control)
LY3437943 (Severe Renal Impairment)
LY3437943 (End-Stage Renal Disease)
LY3437943 administered subcutaneous (SC) to participants with normal renal function
LY3437943 administered SC to participants with severe renal impairment
LY3437943 administered SC to participants with end-stage renal disease